#1 Startup Dataset
Growth rates, revenue data, direct competitors and contact details.
Peter Strumph Email
CEO . Parvus Therapeutics
South San Francisco, CA
LocationPrimary Email
How to contact Peter Strumph
Join and see Peter's contact info for free!Phone
Current Roles
Employees:
23Revenue:
$3.6MAbout
Parvus is pioneering an innovative class of disease-modifying therapeutics - Navacims™ - with best-in-disease potential. Current treatment approaches to autoimmune disease generally require suppression of the immune system to prevent immune attack against a patient's own tissues. In contrast, Navacims represent a paradigm shift in treatment approach wherein the immune system is restored to a balanced ‘response ready' and immune self-tolerant state thru the induction and abundant systemic expansion of disease-specific type 1 regulatory T (TR1) cells. Parvus has demonstrated disease reversal with Navacims in multiple in vivo disease models. Two programs are advancing toward the clinic, the first targeting type 1 diabetes (partnered with Novartis) and the second targeting primary biliary cholangitis (PBC), a progressive disease characterized by chronic inflammation, scarring, and destruction of the bile ducts leading eventually to liver failure.Parvus Therapeutics Address
800 Dubuque AvenueSouth San Francisco, CA
United States